South Korea’s Macrogen unveils new temperature-controlled packaging

15 September 2016 (Last Updated September 15th, 2016 18:30)

South Korea-based biotechnology group Macrogen has launched Easybox, new temperature-controlled packaging for use in the global gene and genome analytics service industry.

South Korea-based biotechnology group Macrogen has launched Easybox, new temperature-controlled packaging for use in the global gene and genome analytics service industry.

Featuring gel packs, packing instructions and other supplies, Easybox can be customised according to customer requirements.

Designed to reduce shipments’ temperature change during their transportation, the solution also allows customers to reduce their shipping preparation time.

"This customised premium temperature-controlled packaging will provide greater convenience for customers."

Macrogen has used waterproof, insulated, shock-absorbing material to create Easybox, in order to enhance protection and maintain its temperature range.

Users can pack their shipments using dry ice or gel packs to decrease temperature variation, costs and accidents.

Macrogen CEO Hyeon-yong Jeong said: “As Macrogen’s customer base is expanding from researchers to clinical diagnosis and general customers, the sample management of customers is ever more complex.

“The launch of this customised premium temperature-controlled packaging, Easybox, will provide greater convenience for customers and manage customers’ samples safely.”

The company aims to provide Easybox to around 18,000 research and development (R&D) customers based in 150 countries.

Macrogen is also planning to increase its global sales of Easybox against the backdrop of an expanding sample management sector.

The company said that its customers can track their Easybox shipments with the help of global express transportation company FedEx Express (FedEx).

In April, Macrogen entered into a deal with National Cancer Center Korea to conduct joint research into genome information-based precision medicine with cancer patients.